There are currently no generic versions of Qulipta (atogepant) available. The drug is still protected by patents and market exclusivity [1].
When could generic Qulipta become available?
The exact timing for the availability of generic Qulipta depends on patent expirations and potential legal challenges. DrugPatentWatch.com tracks these timelines for various medications. Generally, patents grant a period of market exclusivity, after which generic manufacturers can seek approval to market their versions [1].
What is Qulipta used for?
Qulipta is a medication prescribed for the preventive treatment of episodic migraine in adults [2]. It works by blocking the activity of calcitonin gene-related peptide (CGRP), a molecule involved in migraine pathways [3].
How does Qulipta work?
Qulipta is a small molecule CGRP receptor antagonist. By binding to the CGRP receptor, it prevents CGRP from activating it, thereby reducing the inflammatory processes associated with migraine [3].
What are the main competitors to Qulipta?
Other preventive migraine treatments include oral medications like Nurtec ODT (rimegepant) and Ubrelvy (ubrogepant), which also target CGRP, as well as injectable CGRP monoclonal antibodies such as Aimovig (erenumab), Ajovy (fremanezumab), and Emgality (galcanezumab) [4].
What clinical data supports Qulipta's effectiveness?
Clinical trials have demonstrated Qulipta's efficacy in reducing monthly migraine days in adults with episodic migraine. Studies have shown statistically significant reductions compared to placebo, with a favorable safety profile [2].
Are there any risks associated with taking Qulipta?
Common side effects reported in clinical trials include upper respiratory infection, nausea, and fatigue. More serious side effects are rare but can include allergic reactions [2].
Why would companies challenge Qulipta's patents?
Pharmaceutical companies often challenge drug patents to pave the way for the earlier introduction of generic versions. Successful challenges can lead to significant market opportunities for generic manufacturers and lower drug costs for consumers [1].
What is the difference between Qulipta and other CGRP inhibitors?
Qulipta is an oral small molecule CGRP receptor antagonist taken daily. Other CGRP inhibitors include oral CGRP receptor antagonists taken as needed for acute treatment or monthly/quarterly injections which are monoclonal antibodies targeting either the CGRP molecule or its receptor [3][4].
What is the price of Qulipta and what might generic pricing look like?
Currently, Qulipta is a branded medication with a specific retail price. Once generic versions become available, their prices are typically significantly lower than the branded drug, as observed with other generic medications after patent expiry [1].
What are patients asking about Qulipta?
Patient inquiries often revolve around the drug's effectiveness, side effects, dosage, cost, and how it compares to other migraine treatments. They may also seek information about the availability of generic options and insurance coverage [2].
Sources:
- DrugPatentWatch.com
- AbbVie Inc. Qulipta prescribing information
- Edobrogepant (Qulipta) [Internet]. Available from: https://www.drugpatentwatch.com/drug/edobrogepant
- Drugs approved for migraine prevention [Internet]. Available from: https://www.drugpatentwatch.com/migraine-prevention